June 2025 delivered more than $152M in women's health funding (full overview here), but the month's most telling developments happened outside pitch decks and term sheets.
While industry conferences dominated calendars and LinkedIn feeds were full of insights from panel discussions about the future of women's health, the real action unfolded in regulatory offices, acquisition negotiations, and boardrooms.
Between the networking events and keynote speeches, companies were quietly securing FDA approvals, closing strategic acquisitions, and launching products that signal where the category is actually heading.
The funding headlines tell one story: Visby Medical's $55M raise, Commons Clinic's $26M Series B, Eli Health's $12M Series A.
But dig deeper into June's activity and a more nuanced picture emerges: Metabolic health establishing itself as a distinct investment category, provider education becoming a scaling requirement, and passive monitoring partnerships pointing toward the future of continuous health tracking.
Are Instant Diagnostics the Future?
Visby Medical's $55M raise isn't just another big funding round - it suggests that consumers may be willing to pay premium prices to avoid the awkward clinic conversation about STI testing.
Their at-home test delivers PCR-quality results in 30 minutes, eliminating both the clinic visit and the anxious multi-day wait for results.
Eli Health's $12M for instant hormone monitoring follows a different strategy than a large part of our industry: Starting with cortisol measurement rather than reproductive hormones like most cycle trackers.
This entry point suggests plans for a broader wellness-focused go-to-market approach rather than targeting fertility or contraception users first.
The question here isn't whether the technology works - it's that this represents a new habit for many consumers, thus raising questions about sustained consumer engagement and in consequence business model viability.
Metabolic Health as a Category
Veracity's $8M raise might seem modest, but it represents something bigger: Investors treating women's metabolic health as a distinct category rather than cramming it into "general wellness" or "weight management" buckets.
Beyond that companies like Lilli Health emerged from stealth. Lilli Health launched a new PCOS management app targeting insulin resistance this month, and Carrot Fertility introduced a fertility-metabolic health program. This too reflects the category's momentum.
The term "metabolic health" has only really entered women's health innovation and investor vocabulary over the past year or so, but it's quickly becoming one of the hottest investment categories.
This matters because PCOS affects up to 15% of women of reproductive age, and menopause fundamentally alters metabolism for literally every woman who lives long enough.
Turns out that's a pretty big addressable market when you stop treating it as an afterthought.
Non-Drug Period Pain Solutions Gain Investment
Samphire Neuroscience raised $5M for a neurotech wearable targeting menstrual pain.
Translation: Investors are betting that the billions of women who experience period pain might want something more sophisticated than "take some ibuprofen and deal with it."
The timing isn't coincidental - multiple non-drug period pain solutions launched over the past weeks.
Regulatory Milestones Across Categories
June delivered several notable regulatory approvals across different women's health categories.
Clairity received FDA De Novo Authorization for AI-based breast cancer risk prediction.
In Europe, Inne received UK and European approval for its saliva-based contraception method, and Femasys gained European approval for FemBloc non-surgical permanent birth control.
These approvals span AI diagnostics, and novel contraceptive methods, suggesting regulatory pathways are developing across multiple women's health categories rather than being concentrated in any single area.
Strategic Acquisitions
Three strategic acquisitions tell different stories about consolidation priorities.
Hera Biotech buying cervical cancer diagnostic HeraFem suggests point-of-care cancer screening as a next step in their current endometriosis work.
acquisition of PCOS app Ovulai indicates the Swedish telemedicine platform sees condition-specific applications (and their users) as valuable components to grow.>
TMRW acquiring Cryogatt's fertility storage patents shows that in some acquisitions assets matter more than revenue.
Provider Education Addresses Scaling Bottlenecks
The Menopause Society's initiative to train 25,000 healthcare professionals reveals an uncomfortable truth: Most doctors know only little about treating menopause symptoms.
The education initiative's $10M budget suggests the problem is significant enough to require massive intervention rather than incremental continuing education.
This echoes a broader challenge across women's health where companies often find their growth limited not by technology or demand, but by the availability of trained providers who understand women's health conditions.
As documented in previous analysis, several women's health scaleups are investing heavily in provider training programs - from Kindbody's Training Institute to Midi Health's Midi University - recognizing that upskilling clinicians has become essential for growth and category expansion.
Passive Monitoring Partnerships Point to Future
Maven Clinic's partnership with Oura represents the next evolution of women's health platforms. Instead of asking users to manually input symptoms, they integrate with devices they're already wearing.
This speaks to the three key requirements for the future of remote health monitoring: Passive, non-invasive, and continuous.
What Oura has achieved for basal temperature, or heart rate variability will likely be applied to additional biomarkers over the next few years, with hormones already in early development.
What this suggests is that successful women's health companies will increasingly compete on partnerships and data integration capabilities rather than standalone application features.
Key Market Indicators
Overall June's developments suggest several trends worth tracking: Instant diagnostics that eliminate wait times are taking off, metabolic health is establishing itself as a distinct investment category, and provider education has become a scaling requirement rather than a nice-to-have.
The month's activity also highlighted the importance of passive monitoring integration, with successful platforms moving beyond manual data entry toward continuous, device-integrated health tracking.
Strategic acquisitions focused on filling specific capability gaps rather than broad consolidation, suggesting the market remains fragmented enough to reward targeted expertise.
For anyone building in this space, June offered both validation and practical insights.
The validation: Significant capital remains available for solutions that solve specific problems.
The practical insight: Execution across regulatory approval, provider training, and strategic partnerships determines success more than technology innovation alone.
